Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

CJC-1295 vs GHRP-2

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

CJC-1295 and GHRP-2 share the gh-secretagogue class and carry roughly equivalent evidence (Anecdotal + Phase 2 (DAC) / Japan-Approved Diagnostic). On the catalogued data layer CJC-1295 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; CJC-1295's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

CJC-1295

Anecdotal + Phase 2 (DAC)

GHRP-2

Japan-Approved Diagnostic

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: water retention. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

CJC-1295 GHRP-2
Class GHRH analog (no-DAC or DAC forms) GHRP; ghrelin receptor agonist
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life GHS-R1a agonist; strong GH release
Route SC injection SC / Intranasal
Half-life No-DAC ~30 min / DAC ~8 days ~15-30 min
Dosage (research) No-DAC: 100 mcg SC 2x daily pre-bed and pre-workout (Seeds Vol 1 starting protocol, may go up to 300 mcg per dose 3x daily per r/Peptides wiki). DAC: 1 mg SC weekly (Phase 2 starting dose, range up to 2 mg/wk) 100-300 mcg SC 1-3x daily
Evidence tier Anecdotal + Phase 2 (DAC) Japan-Approved Diagnostic
Research depth 44 indexed (PubMed 34 · CT 1 · EPMC 9) 148 indexed (PubMed 139 · CT 0 · EPMC 9)
Availability Compounding Restricted Research
Reported risks Water retention; numbness/tingling; elevated IGF-1; injection site reactions Cortisol/prolactin increase; hunger; water retention

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick CJC-1295 or GHRP-2?

CJC-1295 and GHRP-2 share the gh-secretagogue class and carry roughly equivalent evidence (Anecdotal + Phase 2 (DAC) / Japan-Approved Diagnostic). On the catalogued data layer CJC-1295 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; CJC-1295's evidence base is currently denser.

What is the difference between CJC-1295 and GHRP-2?

CJC-1295 is classed as GHRH analog (no-DAC or DAC forms); GHRP-2 is classed as GHRP; ghrelin receptor agonist. Reported mechanism: CJC-1295, GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life; GHRP-2, GHS-R1a agonist; strong GH release. Reported half-life: CJC-1295, No-DAC ~30 min / DAC ~8 days; GHRP-2, ~15-30 min. Routes in published studies: CJC-1295, SC injection; GHRP-2, SC / Intranasal.

Which has stronger evidence, CJC-1295 or GHRP-2?

CJC-1295 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CJC-1295 is graded Anecdotal + Phase 2 (DAC), with 1 cited source on its reference page and 44 indexed studies. GHRP-2 is graded Japan-Approved Diagnostic, with 1 cited source on its reference page and 148 indexed studies.

Which is more accessible, CJC-1295 or GHRP-2?

Neither CJC-1295 nor GHRP-2 is an FDA-approved drug. Catalog status: CJC-1295, Compounding Restricted; GHRP-2, Research. CJC-1295's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn. FDA lists GHRP-2 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).

Are CJC-1295 and GHRP-2 ever combined?

CJC-1295 and GHRP-2 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…